TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01833897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
Study: NCT04365127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone 100 MG
Description: Subcutaneous administration twice daily
Study: NCT04518475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag combining rituximab
Description: After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~All subjects receive single dose infusion of rituximab 375 mg/m(2) within 14 days after enrollment.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eltrombopag
Description: After enrollment,all subjects receive eltrombopag treatment,the initial dose of eltrombopag administration was an oral 75 mg once daily.Complete blood count including platelet count was done once a week.The dose of eltrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count \>250×10\^9/L, the eltrombopag will stop until the platelet count \<30×10\^9/L.~Efficacy and safety will be evaluated at Week 4, Week 8, and Week 12.
Study: NCT03469141

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure Relief Monitoring System
Description: Biofeedback provided to the intervention group via the smartphone app will include: Visual (e.g., phone notification bar) and auditory reminders if PR (pressure relief) is not performed as scheduled, Real-time feedback during performance of PR maneuvers to ensure adequate PR (e.g., the app will indicate if the duration of PR is sufficient), and Aggregate counts of daily PR activity.
Study: NCT03902249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Study: NCT02694393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
Study: NCT01302639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
Description: EGCG, resveratol and genistein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
Description: EGCG, resveratol and genistein
Study: NCT03587402

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous perineal stimulation
Description: Surface stimulation
Study: NCT01302639

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Comparison of different combinations of polyphenols with respect to effects on fat oxidation
Description: EGCG, resveratol and genistein
Study: NCT04040738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity surgery under general anaesthesia
Description: Forearm, wrist and hand surgery after fentanyl and propofol induction of anaesthesia, with sevoflurane maintenance

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity surgery under regional anaesthesia
Description: Forearm, wrist and hand surgery under brachial plexus block with 0.4 ml/kg of 0.33% bupivacaine solution Other Names: Marcaine 5 mg/ml Astra Zeneca OGYI-T 6496/14
Study: NCT01910701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit
Description: The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
Study: NCT04551027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: compensatory cognitive treatment
Description: a brief group compensatory cognitive intervention including 12 meetings of 1 hour in a group of five and focuses on these cognitive domains: prospective memory, vigilance and attention, memory and learning and executive functions
Study: NCT01416194

Intervention type: DRUG
Intervention: Bazedoxifene
Description: Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

Intervention type: DRUG
Intervention: Bisphosphonate
Description: Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.

Intervention type: DRUG
Intervention: Raloxifene
Description: Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
Study: NCT03970434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Venous blood collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral blood collection
Description: Peripheral blood collection
Study: NCT03358576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Antibiotic for complicated intra-abdominal infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem-Etzadroxil/Probenecid
Description: Antibiotic for complicated intra-abdominal infection
Study: NCT04692753

Intervention type: OTHER
Intervention: Training and education
Description: Training and education of health care workers in the form of online seminars and bed side demonstration of care and maintenance of venous access devices
Study: NCT03537625

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green tea
Description: We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Green tea
Description: We made a dietary supplement from Cammellia sinesis O. Kunze, and made tablets containing extract.
Study: NCT02230228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALK-001 (No generic name)
Description: Daily, oral administration of ALK-001 capsules.
Study: NCT04082533

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients will be receiving 100 mg intravenous hydrocortisone every 8 hours, starting in the holding area roughly 2 hours prior to first incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water (D5W)
Description: Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose 5% in water (D5W)
Description: Patients will be receiving a matched volume of D5W every 8 hours, starting in the holding area roughly 2 hours prior to first incision.
Study: NCT03358576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Antibiotic for complicated intra-abdominal infection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Antibiotic for complicated intra-abdominal infection
Study: NCT04624256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Patients and physicians engage in discussion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo conventional hypofractionated radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo moderate hypofractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT02414165

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC
Description: Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Study: NCT03284515

Intervention type: BIOLOGICAL
Intervention: Vaccination with a pertussis containing vaccine
Description: Vaccination with a pertussis containing vaccine
Study: NCT00798707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 25 mg tablet, once daily dosing for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Description: 50 mg tablet, once daily dosing for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
Study: NCT01742390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone or paliperidone
Study: NCT02741609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Borrelia Diagnostic Test
Description: The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
Study: NCT04327609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION SLR™ DEB
Description: Subjects will receive standard high-pressure balloon angioplasty followed by local application of sirolimus with the SELUTION SLR™ 018 DEB (MedAlliance) of appropriate diameter and length to achieve full lesion coverage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: The control arm will receive standard high-pressure balloon angioplasty of appropriate diameter and length and no further lesion treatment.
Study: NCT00537056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG PET CT
Description: nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI
Description: DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
Study: NCT03587402

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anal stimulation
Description: Intra-cavitary stimulation
Study: NCT01894919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (1 dose at study month zero)
Study: NCT03358576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Clavulanate
Description: Antibiotic for complicated intra-abdominal infection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem
Description: Antibiotic for complicated intra-abdominal infection
Study: NCT03996928

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study: NCT02053727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04142541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System)
Description: The Neuroguard® IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection is indicated for improving the carotid luminal diameter in patients with clinically significant carotid artery stenosis and for the simultaneous capture and removal of embolic material during angioplasty and stenting.
Study: NCT03927157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Tezepelumab
Description: Tezepelumab subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study: NCT02285751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Study: NCT00537056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 Fluoro-deoxi-glucose
Description: 15 mCi iv
Study: NCT02285751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Study: NCT01989533

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad4-mgag
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad4-mgag
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-mgag
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-mgag
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad4-EnvC150
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ad4-EnvC150
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvC150
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad4-EnvC150
Description: Ad4 live virus vaccine with an HIV insert

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: gp 120 Protein Boost
Description: HIV protein boost

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: gp 120 Protein Boost
Description: HIV protein boost

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp 120 Protein Boost
Description: HIV protein boost

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp 120 Protein Boost
Description: HIV protein boost
Study: NCT01175694

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Interstitial multicatheter brachytherapy
Description: Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
Study: NCT05589545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
Description: A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by an ensemble of standard dental implants and zygomatic dental implants, following the All-on-4 Hybrid Concept.
Study: NCT03899116

Intervention type: OTHER
Intervention: deflation of pneumatic tourniquet
Description: gradual deflation with variable degrees

Intervention type: OTHER
Intervention: deflation of pneumatic tourniquet
Description: gradual deflation with variable degrees

Intervention type: OTHER
Intervention: deflation of pneumatic tourniquet
Description: gradual deflation with variable degrees
Study: NCT00192179

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine trivalent (CAIV-T)
Description: The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10\^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10\^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consisted of physiologic normal saline.
Study: NCT05571501

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait assessment using the GAITRIte walkway
Description: 10-20 walking assessment using the GAITRite walkway

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait assessment using the GAITRIte walkway
Description: 10-20 walking assessment using the GAITRite walkway
Study: NCT03980847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate 20 mg
Description: The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate 20 mg
Description: The Alendronate 20 mg combined with nanocrystalline hydroxyapatite as a synthetic bone substitute for socket preservation after tooth extraction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nanocrystal hydroxyapatite
Description: Postextraction Sockets Preserved With Nanocrystal hydroxyapatite as a synthetic bone substitute alone as a bone graft
Study: NCT02565797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DabirAIR alternating pressure overlay
Description: DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DabirAIR alternating pressure overlay
Description: DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
Study: NCT00844545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
Study: NCT02558608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DIPL
Description: dissection of the inferior pulmonary ligament

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: WR
Description: wedge resection of the lung bleb

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WR
Description: wedge resection of the lung bleb

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoscopic surgery
Description: surgery performed by video assisted thoracoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoscopic surgery
Description: surgery performed by video assisted thoracoscopy
Study: NCT01894919

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (1 dose at study month zero)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine (1 dose at study month zero)
Study: NCT00537056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium-DTPA
Description: 0.1 mmol/kg iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg/day po
Study: NCT04795973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time-restricted fasting for 4 weeks
Description: eat ad libitum from 7am to 5pm and fast in other time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5:2 regimen for 4 weeks
Description: chose two non-consecutive days per week to eat very little and eat ad libitum the other 5 days of the week